Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.21.1
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Organization And Summary Of Significant Accounting Policies [Line Items]    
Cash, cash equivalents, and marketable securities $ 207.4  
Revenue | Credit Risk | Vertex Pharmaceuticals Inc    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 63.00% 35.00%
Revenue | Credit Risk | Takeda Pharmaceuticals Inc    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 7.00% 8.00%
Revenue | Credit Risk | BMS    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 30.00% 0.00%
Other Assets    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Restricted cash $ 3.7